GlassScriptPhysician profile
Megan Reed
NPI 1487003208
$1,571.68
in general payments reported to CMS, 2019-2025
26 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $446 · 2023: $289 · 2024: $440 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.54 | 2021-2024 | Farxiga, Airsupra |
| Pfizer INC. | $123.51 | 2023-2025 | |
| Lilly USA, LLC | $102.97 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $102.52 | 2021-2023 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $63.46 | 2021-2023 | Arexvy |
| Organon LLC | $59.87 | 2022-2025 | Nexplanon |
| Exact Sciences Corporation | $58.91 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $46.06 | 2021 | |
| Phathom Pharmaceuticals, INC. | $45.83 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $33.93 | 2022-2024 | Spravato |
| Bioventus LLC | $33.02 | 2022 | |
| Merck Sharp & Dohme LLC | $25.16 | 2023 | Dificid, Pifeltro |
| Abiomed | $24.29 | 2023 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $22.62 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21.67 | 2025 | Ohtuvayre |
| Exeltis, USA INC. | $21.43 | 2024 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.07 | 2023 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $19.96 | 2024 | Austedo Xr |
| Inspire Medical Systems, INC. | $19.80 | 2024 | Inspire |
| Ironshore Pharmaceuticals INC. | $17.90 | 2023 | Jornay Pm |
| Sanofi Pasteur INC. | $17.56 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.82 | 2024 | |
| Alk-Abello, INC | $15.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.42 | 2021 | |
| Corium, LLC | $11.72 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.